Analyst Reco. Emergent BioSolutions Inc.

Equities

EBS

US29089Q1058

Real-time Estimate Cboe BZX Other stock markets 09:47:40 29/04/2024 pm IST			5-day change	1st Jan Change
1.93 ^USD	+0.52%		-10.64%	-19.58%

24/04	Amneal Pharmaceuticals Cleared by FDA to Sell Generic Version of Nasal Spray to Treat Opioid Overdose -- Shares Rise	MT
25/03	Emergent Gets FDA's 'No Action Indicated' Status For Baltimore Bayview Manufacturing Facility	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Benchmark Upgrades Emergent Biosolutions to Buy From Hold, Price Target is $5	07/03	MT
Benchmark Downngrades Emergent Biosolutions to Hold From Buy	29/23/29	MT
Benchmark Upgrades Emergent Biosolutions to Buy From Hold, Price Target is $22	10/23/10	MT
JPMorgan Downgrades Emergent Biosolutions to Underweight From Neutral, Adjusts Price Target to $9 From $23	17/23/17	MT
Chardan Cuts Price Target on Emergent Biosolutions to $55 From $65 on Slower Revenue, Profitability Growth; Keeps Buy Rating	09/22/09	MT
Cowen Trims Emergent Biosolutions Price Target to $29 From $30, Maintains Market Perform Rating	12/22/12	MT
Wells Fargo Adjusts Emergent Biosolutions' Price Target to $38 from $46, Keeps Equalweight Rating	04/22/04	MT
Cantor Fitzgerald Cuts Emergent Biosolutions to Neutral From Overweight, Price Target to $33 From $55	02/22/02	MT
JPMorgan Trims Price Target for Emergent Biosolutions to $57 From $58, Maintains Neutral Rating	10/22/10	MT
Wells Fargo Adjusts Emergent Biosolutions' Price Target to $40 from $37, Keeps Equalweight Rating	10/22/10	MT
Benchmark Upgrades Emergent Biosolutions to Buy from Hold, Sets $77 Price Target	20/22/20	MT
Cantor Fitzgerald Adjusts Price Target on Emergent Biosolutions to $55 From $50, Reiterates Overweight Rating	20/22/20	MT
Chardan Adjusts Price Target on Emergent Biosolutions to $75 From $92, Maintains Buy Rating	10/21/10	MT
Benchmark Capital Downgrades Emergent Biosolutions to Hold From Buy	08/21/08	MT
EMERGENT BIOSOLUTIONS : Argus Research Downgrades Emergent Biosolutions to Hold From Buy	05/21/05	MT
EMERGENT BIOSOLUTIONS : Chardan Adjusts Price Target on Emergent Biosolutions to $92 From $112, Maintains Buy Rating	01/21/01	MT
EMERGENT BIOSOLUTIONS : Benchmark Adjusts Price Target on Emergent Biosolutions to $120 From $150, Maintains Buy Rating	30/21/30	MT
EMERGENT BIOSOLUTIONS : Guggenheim Adjusts Price Target on Emergent Biosolutions to $110 From $130, Maintains Buy Rating	14/21/14	MT
EMERGENT BIOSOLUTIONS : Benchmark Starts Emergent Biosolutions at Buy with $150 Price Target	07/21/07	MT
EMERGENT BIOSOLUTIONS : Chardan Upgrades Emergent BioSolutions to Buy From Neutral, Maintains $112 Price Target	24/21/24	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Emergent BioSolutions Inc.

Equities

EBS

US29089Q1058

Analyst Reco.

Filters